Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT
SHARE REPURCHASE

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

In accordance with the Shareholders' resolution passed by the Shareholders at the annual general meeting held on June 12, 2026, the directors of the Company (the "**Directors**") were granted a general mandate to repurchase up to 256,819,861 shares of the Company (the "**Shares**"), representing 10% of the total number of Shares in issue as of June 12, 2026 (the "**Repurchase Mandate**").

On August 20, 2026, the board of Directors (the "**Board**") resolved to utilize the Repurchase Mandate to repurchase Shares in the open market as appropriate at the aggregate amount of not exceeding RMB1,000 million (the "**Proposed Share Repurchase**"). The period for the Proposed Share Repurchase is from August 21, 2026 until (a) the date of the next annual general meeting, (b) the date by which the next annual general meeting of the Company is required to be held by the articles of association of the Company or any applicable law, or (c) the date upon which such authority is revoked or varied by an ordinary resolution of the Shareholders at a general meeting of the Company, whichever is the earliest. The Proposed Share Repurchase will be funded by the Company's internal resources. The Company will conduct the Proposed Share Repurchase in compliance with the articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and all other applicable laws and regulations.

The Board believes that a share repurchase in the present conditions will demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to the Shareholders. In addition, the Board believes that the current financial resources of the Company would enable it to implement the Proposed Share Repurchase while maintaining a solid financial position.

Shareholders and potential investors should note that the exercise of the Repurchase Mandate by the Company will be subject to market conditions and will be at the absolute discretion of the Board. There is no assurance of the timing, quantity or price of any repurchases. Shareholders and potential investors should exercise caution when dealing in the Shares.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, August 20, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. TANG Renhong as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.